Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.
Tanaka A, Sata M, Okada Y, Teragawa H, Eguchi K, Shimabukuro M, Taguchi I, Matsunaga K, Kanzaki Y, Yoshida H, Ishizu T, Ueda S, Kitakaze M, Murohara T, Node K; PROTECT study investigators. Tanaka A, et al. Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):165-172. doi: 10.1093/ehjcvp/pvac059. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 36308299 Free PMC article. Clinical Trial.
Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study.
Kusunose K, Yoshida H, Tanaka A, Teragawa H, Akasaki Y, Fukumoto Y, Eguchi K, Kamiya H, Kario K, Yamada H, Sata M, Node K; PRIZE Study Investigators. Kusunose K, et al. Among authors: tanaka a. Hypertens Res. 2022 Jan;45(1):106-115. doi: 10.1038/s41440-021-00752-9. Epub 2021 Oct 17. Hypertens Res. 2022. PMID: 34657137 Free PMC article. Clinical Trial.
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Shiina K, Tomiyama H, Tanaka A, Imai T, Hisauchi I, Taguchi I, Sezai A, Toyoda S, Dohi K, Kamiya H, Kida K, Anzai T, Chikamori T, Node K; CANDLE trial investigators. Shiina K, et al. Among authors: tanaka a. Hypertens Res. 2023 Feb;46(2):495-506. doi: 10.1038/s41440-022-01085-x. Epub 2022 Nov 15. Hypertens Res. 2023. PMID: 36380202
Relationship Between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients With Diabetes and Mild Heart Failure: Results From the CANDLE Trial.
Nakatani D, Dohi T, Hikoso S, Tanaka A, Nanasato M, Shimizu W, Node K, Sakata Y; CANDLE Trial Investigators. Nakatani D, et al. Among authors: tanaka a. J Cardiovasc Pharmacol. 2023 Jul 1;82(1):61-68. doi: 10.1097/FJC.0000000000001430. J Cardiovasc Pharmacol. 2023. PMID: 37070931 Clinical Trial.
Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED).
Tanaka A, Okada Y, Torimoto K, Kamei N, Hirai H, Kono T, Sugimoto K, Teragawa H, Taguchi I, Maruhashi T, Sonoda S, Kurozumi A, Inagaki S, Oshita C, Hisauchi I, Takahashi K, Higashi Y, Shimabukuro M, Node K; PROCEED Trial Investigators. Tanaka A, et al. Diabetes Metab. 2023 Jul;49(4):101447. doi: 10.1016/j.diabet.2023.101447. Epub 2023 Apr 26. Diabetes Metab. 2023. PMID: 37116858 Clinical Trial. No abstract available.
Recommendation for Appropriate Use of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
Tanaka A, Kinugawa K, Kuwahara K, Ito H, Murohara T, Hirata KI, Node K; administrative board members of the Japanese Circulation Society and the Japanese Heart Failure Society. Tanaka A, et al. Circ J. 2023 Oct 25;87(11):1707-1709. doi: 10.1253/circj.CJ-23-0605. Epub 2023 Sep 22. Circ J. 2023. PMID: 37743518 Free article. No abstract available.
6,406 results